Abstract
Abstract Introduction: Seizures affect up to 50% of patients with meningioma. Anti-epileptic drugs (AEDs) cause adverse effects in ~20% of patients. Guidelines recommend against routine use of prophylactic AEDs. The aim of this study was to evaluate the use of AEDs in meningioma surgery in the UK. Materials and methods: Email survey of UK neurosurgeons to ascertain: (i) use of prophylactic AED; (ii) preferred AED, dose and duration of use; (iii) tumour location and radiological factors that influence use of AED; (iv) willingness to participate in a future randomised controlled trial. Results: 60 completed surveys from 25 neurosurgical centres. Use of prophylactic AED was ‘almost never’ in 37/61 (61%); ‘rarely’ 10/61 (16%); ‘often’ 8/61 (13%) and ‘almost always’ 6/61 (10%). 42 surgeons had prescribed AEDs at some point; Levitoracetam (n=23) and phenytoin (n=18) were the commonest. Duration of prescription ranged from single dose at surgery to 3 months. Commonest duration was 7 days (n=18) and 14 days (n=8). Sphenoid (24/49; 49%) and olfactory (17/49; 35%) location, oedema (26/49; 53%) and mass effect/midline shift (20/49; 41%) were factors associated with prophylactic AED use. 80% of surgeons would participate in a randomised controlled trial. Conclusions: Most UK neurosurgeons follow guidelines and do not routinely prescribe prophylactic AEDs. Sphenoid and olfactory meningiomas and those with oedema are more likely to receive prophylactic AEDs which suggests neurosurgeons are more concerned about the consequences of seizures in these patients. A randomised controlled trial is required to provide class I evidence of those patients that may benefit from prophylactic AEDs in meningioma surgery and a proposal will be presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.